NLRP3 and Myocardial fibrosis: Therefore, in murine models of myocardial ischemia–reperfusion injury, administration of an orally available NLRP3 inhibitor, OLT1177 (dapansutrile), within 60 min of reperfusion significantly limited necrosis and consecutively prevented the development of secondary myocardial fibrosis and LV systolic dysfunction in a dose-dependent manner, through selective inhibition of the NLRP3 inflammasome [169].